Skip to main content
PMC home page
Gastroenterology Research and Practice logoLink to Gastroenterology Research and Practice
. 2015 Sep 14;2015:245460. doi: 10.1155/2015/245460

Prevalence of Splanchnic Vein Thrombosis in Pancreatitis: A Systematic Review and Meta-Analysis of Observational Studies

Wenda Xu 1, Xingshun Qi 2, Jiang Chen 2, Chunping Su 3, Xiaozhong Guo 2,*
PMCID: PMC4584234  PMID: 26451142

Abstract

Splanchnic vein thrombosis (SVT) may be negatively associated with the prognosis of pancreatitis. We performed a systematic review and meta-analysis of literatures to explore the prevalence of SVT in pancreatitis. All observational studies regarding the prevalence of SVT in pancreatitis were identified via PubMed and EMBASE databases. The prevalence of SVT was pooled in the total of patients with pancreatitis. And it was also pooled in the subgroup analyses according to the stage and causes of pancreatitis, location of SVT, and regions where the studies were performed. After the review of 714 studies, 44 studies fulfilled the inclusion criteria. Meta-analyses showed a pooled prevalence of SVT of 13.6% in pancreatitis. According to the stage of pancreatitis, the pooled prevalence of SVT was 16.6% and 11.6% in patients with acute and chronic pancreatitis, respectively. According to the causes of pancreatitis, the pooled prevalence of SVT was 12.2% and 14.6% in patients with hereditary and autoimmune pancreatitis. According to the location of SVT, the pooled prevalence of portal vein, splenic vein, and mesenteric vein thrombosis was 6.2%, 11.2%, and 2.7% in pancreatitis. The prevalence of SVT in pancreatitis was 16.9%, 11.5%, and 8.5% in Europe, America, and Asia, respectively.

1. Introduction

Splanchnic vein thrombosis (SVT) is one such vascular complication of pancreatitis. SVT involves the portal vein (PV), splenic vein (SplV), and mesenteric vein (MV) with the occurrence in combination or separately [1]. The consequence of pancreatitis-induced SVT may generate a localized form of portal hypertension and then splenoportal or gastroepiploic systems burden following localized venous hypertension and lead to gastric, oesophageal, or colonic varices. It may also cause the liver failure, bowel ischemia, and gastrointestinal bleeding [2]. Patients suffer from great pain and potentially lethal threaten. The limited literature cannot acquire an exact prevalence of SVT in pancreatitis. The aim of the present systematic review and meta-analysis is to obtain the prevalence of SVT in pancreatitis by resolving the following three questions. (1) What is the prevalence of SVT in pancreatitis, including PVT, SplVT, and MVT? (2) What is the prevalence of SVT in different types of pancreatitis? (3) What is the prevalence of SVT in pancreatitis in different regions? This study is conducted according to the guidelines for the reporting of meta-analysis of observational studies, which were published by the Meta-analysis of Observational Studies in Epidemiology Group in 2000 [3].

2. Methods

As a systematic review and meta-analysis were planned, we reviewed standard guidelines to conduct meta-analysis studies according to a protocol determined before the study, including study objectives, prespecified eligibility criteria, and methods of statistical analysis.

2.1. Eligibility Criteria

  1. The participants of any age were diagnosed with pancreatitis, including acute pancreatitis (AP), chronic pancreatitis (CP), hereditary pancreatitis (HP), or autoimmune pancreatitis (AIP). The participants with underlying malignancy, cirrhosis, trauma, abdominal surgery unrelated to ongoing pancreatitis, pregnancy, intra-abdominal infections, primary myeloproliferative disorders, or other pancreatic diseases or pancreatitis and resultant SVT were not deliberately excluded.

  2. All cohort and case-control studies were eligible, regardless of the retrospective or prospective nature of the study; case reports were excluded.

  3. Reviews, comments, or letters on the relationship of pancreatitis and SVT were excluded.

  4. Animal studies were also excluded.

  5. There was no publication date or publication status restrictions.

  6. There were no language restrictions.

  7. The number of participants in any included study was beyond 10.

2.2. Search Strategy

The MEDLINE and EMBASE databases were searched using a search strategy from their inception to July 2014. Search items combined keywords and medical subject heading terms (MeSH) were listed as follows: (“pancreatitis” (MeSH Terms) or “pancreatitis” (All Fields)) and ((“portal vein” (MeSH Terms) or (“portal” (All Fields) and “vein” (All Fields)) or “portal vein” (All Fields)) and (“thrombosis” (MeSH Terms) or “thrombosis” (All Fields))) or ((“splenic vein” (MeSH Terms) or (“splenic” (All Fields) and “vein” (All Fields)) or “splenic vein” (All Fields)) and (“thrombosis” (MeSH Terms) or “thrombosis” (All Fields))) or ((“mesenteric veins” (MeSH Terms) or (“mesenteric” (All Fields) and “veins” (All Fields)) or “mesenteric veins” (All Fields) or (“mesenteric” (All Fields) and “vein” (All Fields)) or “mesenteric vein” (All Fields)) and (“thrombosis” (MeSH Terms) or “thrombosis” (All Fields))). The last search was performed on July 29, 2014. The reference lists of the included articles were further hand-searched to identify any additional relevant studies. When the same data were found in more than one publication, only the studies with more complete data and more extensive interval of enrolment were included in the meta-analysis. Full-texts were found by three investigators (Wenda Xu, Xingshun Qi, and Chunping Su).

2.3. Data Extraction

Using a predefined protocol, two investigators (Wenda Xu and Xingshun Qi) independently reviewed the titles and abstracts of all references to identify studies for inclusion in the analysis. Dealing with disagreement between the two reviewers, a consensus was achieved through discussion among all of the reviewers. A schematic diagram depicting reference flow is shown through the systematic review process. Additionally, a data extraction sheet was generated that included authors, publication year, study design, country where the study was conducted, period of enrolment, inclusion and exclusion criteria, type of diseases (AP, CP, HP, or AIP), total sample size, demographic data (age and gender), number of patients with PVT, SplV, or MVT, and proportion of patients with PVT, SplV, or MVT, respectively.

2.4. Evaluation of Study Quality

Quality assessment of studies was carried out independently by two reviewers (Wenda Xu and Xingshun Qi). Discrepancies of interpretation and comprehension were resolved by consensus. The higher quality studies should fulfill the following predetermined criteria.

  1. Country where the study was conducted, interval of enrolment, inclusion and exclusion criteria, and participant characteristics (age, gender) were clearly recorded.

  2. Pancreatitis was diagnosed on the basis of history, clinical manifestations, elevated serum lipase and amylase, imaging detection by ultrasonography (US), endoscopic ultrasonography (EUS), computed tomography (CT), magnetic resonance imaging (MRI), or endoscopic retrograde cholangiopancreatography (ERCP), and/or typical histopathology.

2.5. Data Synthesis and Statistical Analysis

The proportion of pancreatitis patients with SVT in each study was combined to give a pooled prevalence of SVT for all studies. With this method, the pooled prevalence of PVT, SplV, and MVT was calculated. Furthermore, according to the type of pancreatitis and continents (Europe, America, and Asia), the pooled prevalence of SVT, PVT, SplV, and MVT was also created. The number and crude proportion of participants with SVT recorded by each study were used to pool the overall proportion, using the DerSimonian-Laird random-effects method. Between-study heterogeneity was assessed by using the I 2 index (I 2 > 50% was considered having substantial heterogeneity) and the Chi-squared test (P < 0.01 was considered representing significant statistical heterogeneity) [4]. Individualized random effects meta-analyses were performed to estimate percentages and 95% confidence intervals (CIs) for all endpoints queried. Analyses were conducted using StatsDirect statistical software version 2.7.8 (StatsDirect Ltd, Sale, Cheshire, UK).

3. Results

3.1. Description of the Included Studies

In the initial search strategy, a total of 947 studies were selected. Among them, 714 studies were retrieved by removing duplicate research. Two additional unique references were found through reference lists of an original article and a review, respectively [5, 6]. One study as object of related comment was also identified [7]. Total of 44 studies were included in the meta-analysis (Figure 1). Additionally, five studies recorded by the same study team in different publications were excluded [8–12] and one study which concerned the same patients by the same first author in different publications was also excluded [13]. Another study was excluded because the number of participants was <10 [14]. Twenty-two of 44 studies were conducted in Europe [6, 15–35], fourteen in America [2, 5, 7, 36–46], and eight in Asia [47–54]. Among 10441 participants, 874 patients with SVT were screened. These patients included 197 patients with PVT, 525 with SplV, and 72 with MVT. The detailed characteristics of these included studies were shown in Table 1.

Figure 1.

Figure 1

Open in a new tab

Flow diagram of study selection.

Table 1.

Overview of included studies.

Authors (publication year) Type of research Country Interval of enrolment Eligibility criteria Type of disease (AP, CP, HP, or AIP) Number of total samples SVT PVT SlpVT MVT Mean age (range years) Female/
male
Sisman et al.  
(2014) [19]		 Retrospective  cohort study Turkey 2007–2011 NA   CP 65 13 NA 13 NA NA 14/51
Britton et al.  
(2014) [18]		 Retrospective  cohort study UK 1998–2012 Exclusion criteria: 46 cases were excluded from the final analysis as imaging reports made no comment on the portal venous system. AP   145 90 90 NA NA 56.1 NA
Talukdar et al.  
(2014) [47]		 Prospective   cohort study India August 2011 to October 2012 Inclusion criteria: patients over 18 yrs with a primary diagnosis of first episode of AP from August 2011 to October 2012, and prospectively followed for at least six months after discharge or till death; exclusion criteria were (1) recurrent AP; (2) patient who did not get a CT scan. AP   163 12 3 9 NA NA 40/123
Easler et al.  
(2014) [38]		 Prospective study USA June 2003 and April 2010 Inclusion criteria: SAP patients who were admitted with their first AP attack; exclusion criteria: patients with a history of AP or CP. AP   162 22 8 19 6 55 ± 20 78/84
Castiñeira-Alvariño et al.  
(2013) [20]		 Prospective study Spain Since 2007 Inclusion criteria: patients with age <18 years at index visit to the CP outpatient clinic; exclusion criteria: patients who clearly modified the diet before the index visit were excluded.   CP 168 5 5 NA NA 44
(17–76)		 40/128
Suero et al.  
(2013) [21]		 Retrospective study Spain NA NA   AIP 25 6 NA NA NA (17–79) 2/23
Marra-López et al.  
(2013) [22]		 Prospective cohort study Spain 2011–2013 Inclusion criteria: CP patients defined by M-ANNHEIM.   CP 85 9 NA 9/85 NA 59.38 17/68
Harris et al.  
(2013) [2]		 Retrospective study USA January 1996 to December 2006 Inclusion criteria: an institutional (Mayo clinic) database search was done using the key terms acute pancreatitis and superior mesenteric vein thrombosis (SMVT), portal vein thrombosis (PVT), and splenic vein thrombosis (SplVT) from January 1996 to December 2006; exclusion criteria: (1) patients with precipitating factors for thrombosis (abdominal surgery unrelated to ongoing pancreatitis, trauma, pregnancy, cirrhosis, intra-abdominal infections, pancreatic cancer, and primary myeloproliferative disorders) were excluded. (2) All cases of chronic pancreatitis were also excluded. AP   2454 45 20 30 17 NA NA
Jakchairoongruang and Arjhansiri  
(2013) [48]		 Retrospective study Thailand January 1, 2005 and April 30, 2010 Exclusion criteria: six hundred and eight patients were excluded from the study population because of the following reasons: it was not the first episode of acute pancreatitis, the initial CT was not performed, there are no available CT images on our Pictures Archiving and Communications System (PACS), or patient was imaged with only unenhanced CT. AP   72 1 NA 1/72 NA 47.7
(6–89) 		33/39
Ishikawa et al. (2012) [49] Retrospective study Japan July 2003 and October 2010 Inclusion criteria: patients who met the International Consensus Diagnostic Criteria (ICDC) for AIP.   AIP 54 1 1 NA NA 63.2 ± 13.5 (28–86) 6/48
Sisman et al.  
(2012) [24]		 Retrospective study Turkey 2007–2011 Exclusion criteria: patients who received previous H. pylori eradication treatment and who are with any malignancy were excluded.   CP 64 11 NA 11 NA NA NA
De León et al.  
(2012) [25]		 Retrospective study Spain NA NA   AIP 16 4 NA 4 NA 46.6 (17–73) 1/15
Vyas et al.  
(2012) [23]		 Retrospective study UK NA NA AP   87 22 NA 12 NA NA 35/52
Muddana et al.  
(2012) [39]		 Prospective study USA 2003–2010 NA AP   251 41 NA 35 NA 51.5 ± 19 123/128
Rebours et al.  
(2012) [17]		 Prospective single-center study France 2000–2009 Included criteria: all of the in- or outpatients with recurrent acute or chronic alcoholic pancreatitis and followed prospectively based on a standardized protocol, including a yearly physical examination and a search for exocrine pancreatic insufficiency, diabetes, and cholestasis; excluded criteria: (1) cirrhosis; (2) patients who were lost to follow-up in 2009. AP or CP 119 41 14 38 10 NA 19/100
Gonzelez et al.  
(2011) [15]		 Retrospective study UK January 1, 2008, and December 31, 2009 Excluded criteria: patients with chronic pancreatitis, known malignancy, cirrhosis, or established portal hypertension. AP   127 20 10 14 3 53.5 (36–81) 118/9
Shalimar et al.  
(2011) [36]		 Prospective study USA NA Inclusion criteria: patients with CP after an informed consent and ethical clearance; exclusion criteria: NA.   CP 226 9 NA 9 NA NA 48/178
Huggett et al.  
(2011) [16] 		Prospective study UK 2004–2010 Inclusion criteria: patients with AIP and with a median follow-up from diagnosis of 32 months (range 0–76)   AIP 52 7 NA NA NA 59
(26–85)		 11/41
Chowdhury et al.  
(2011) [50]		 Retrospective study India January 2005 and December 2009 Inclusion criteria: children diagnosed with chronic pancreatitis (on imaging study).   CP 73 4 NA NA NA NA 22/51
Chooklin and Hranat (2009) [26] Retrospective study Ukraine NA NA AP   20 4 NA 4 NA NA 3/17
Vege et al.  
(2009) [37]		 Retrospective study USA 1989–2007 Exclusion criteria: patients with preexisting portal hypertension were excluded. AP   1155 50 3 29 4 NA NA
Keck et al.  
(2009) [27]		 Retrospective study Germany In Germany: 2001–2005; in USA: 1995–2005 Excluded criteria: three patients whose predominant lesion was only a very dilated pancreatic duct and who were thus selected for lateral pancreaticojejunostomy.   CP 93 14 NA 14 NA NA 31/62
Raina et al.  
(2009) [5]		 Retrospective study USA 1998–2007 Exclusion criteria: three other malignancies (gastric cancer, the recurrence of gastric adenocarcinoma, and pancreatic adenocarcinoma).   AIP 26 4 NA 4 NA 62.5 (23–86) 9/17
Agarwal et al.  
(2008) [51]		 Retrospective study India January 1996 and December 2005 NA   CP 157 34 NA 34 NA NA NA
Mortelé et al.  
(2004) [40]		 Retrospective study USA 17-month period NA AP   100 46 13 19 14 51 (12–80) 47/53
Makowiec et al.  
(2004) [28]		 Prospective study Germany 1994–2001 Exclusion criteria: 12 patients with portal hypertension and 9 patients underwent splenectomy without splenic vein thrombosis.   CP 177 NA NA 39 NA NA NA
Pimentel et al.  
(2003) [41]		 Retrospective study Brazil 1989–2002 NA   CP 64 2 NA NA NA NA 14/50
Malíková et al.  
(2002) [29]		 Retrospective study Czech Republic NA NA AP   40 NA 2 7 4 NA NA
Mortelé et al.  
(2001) [42]		 Retrospective study USA April 1996 and August 1997 NA AP   100 19 NA 19 NA NA 47/53
Sakorafas et al.  
(2000) [43]		 Prospective study USA 1976–1997 NA   CP 484 34 NA 34 NA NA NA
Dörffel et al.  
(2000) [30]		 Prospective study Germany 38 months Included criteria: definite diagnosis of acute pancreatitis as detected by ultrasonography (US) and CT, elevated serum lipase and amylase, compatible clinical picture, onset of pain symptoms not more than 3 days before admission, no history of pancreatitis, and no deficiencies in antithrombin III, protein C, and protein S. AP   189 45 11 28 6 43 (19–80) 49/140
Arotcarena et al.  
(1999) [31]		 Prospective study France April 1993 to April 1996 NA   CP 494 73 NA NA NA NA NA
Tsushima et al.  
(1999) [52]		 Retrospective study Japan April 1993 and August 1997 Included criteria: patients with AP underwent initial abdominal CT within 3 days after the onset of symptoms and received at least one additional CT examination thereafter; Excluded criteria: cases of traumatic or postoperative pancreatitis AP   25 1 NA 1 NA 53.4 ± 20.8 (25–83) 7/18
Takase et al.  
(1997) [54]		 Prospective study Japan During the past 10 years Exclusion criteria: 6 patients underwent pancreatoduodenectomy or biopsy without the splenic vein specimens   CP 12 5 NA 5 NA 48.8 0/12
Friess et al.  
(1997) [32]		 Retrospective study Greece NA NA   CP 397 21 NA NA NA NA NA
Lin et al.  
(1997) [53]		 Prospective study Taiwan 1976–1996 NA   CP 90 5 NA 5 NA NA NA
Bernades et al.  
(1992) [6]		 Prospective longitudinal Study France January 1980 and March 1990 Inclusion criteria: patients who met the criteria of CP and who had been followed-up during observation; exclusion criteria: patients with cirrhosis.   CP 266 35 10 22 3 40.5 (6–77) 35/231
Nordback et al. (1989) [35] Retrospective study Finland 1972–1986 NA AP or CP 1268 6 2 2 4 NA NA
Rogers and Klatt  
(1989) [44]		 Retrospective autopsy case-control study USA January 1958 and December 1987 Inclusion criteria: cases were included for study if acute pancreatitis was the immediate or contributing cause of death and the portal venous system (both splenic and portal veins) was examined completely at autopsy. Exclusion criteria: patients were excluded from study if there had been a splenectomy or if chronic pancreatitis was present microscopically. AP   72 11 NA 11 NA NA 20/52
Hofer et al.  
(1987) [45]		 Prospective study USA 1975–1985 NA   CP 50 11 NA 11 NA 50 (13–75) 24/26
Roesch et al.  
(1981) [33]		 Retrospective study Germany NA NA   CP 531 27 NA 27 NA 42.5 49/482
Sibert (1978) [34] Retrospective study UK NA NA HP   72 5 2 3 NA NA NA
McElroy and Christiansen  
(1972) [46]		 Retrospective study USA NA NA HP   26 5 3 2 NA NA NA
Gross (1958) [7] Prospective study USA 1956 NA AP or CP 125 2 NA 1 1 49 (6–75) 34/91
Open in a new tab

NA: the data are not available; AP: acute pancreatitis; CP: chronic pancreatitis; HP: hereditary pancreatitis; AIP: autoimmune pancreatitis; SVT: splanchnic vein thrombosis; PVT: portal vein thrombosis; SlpVT: splenic vein thrombosis; MVT: mesenteric vein thrombosis.

3.2. Quality of the Included Studies

The involved countries of all studies could be found. Interval of enrolment was unavailable in ten of the 44 studies. Twenty-one studies had no eligibility criteria; eight of the remaining 23 studies had detailed inclusion and exclusion criteria. Demographic data were completely recorded in nineteen studies. The pancreatitis diagnostic criteria were not elaborate in nine studies only with abstracts and one study with full-test.

3.3. Prevalence of SVT in Pancreatitis

A meta-analysis of involved studies meeting eligibility criteria showed the prevalence of SVT in patients with pancreatitis, ranging from 0.5% to 62.1% (Figure 2). A pooled prevalence was 13.6% (95% CI: 10.2%–17.4%) with a statistically significant heterogeneity among studies (I 2 = 96.2%, 95% CI: 95.7%–96.6%, P < 0.001).

Figure 2.

Figure 2

Open in a new tab

Forest plots showing the prevalence of splanchnic vein thrombosis (SVT) in pancreatitis.

3.4. Prevalence of PVT, SplVT, and MVT in Pancreatitis

Seventeen studies reported the prevalence of PVT in patients with pancreatitis, ranging from 0.2% to 62.1% (Figure 3(a)). A pooled prevalence was 6.2% (95% CI: 32.9%–10.7%) with a statistically significant heterogeneity among studies (I 2 = 97.1%, 95% CI: 96.6%–97.6%, P < 0.001). The analysis of patients with SplVT in pancreatitis showed that the prevalence ranged from 0.2% to 41.7% (Figure 3(b)). A pooled prevalence was 11.2% (95% CI: 8.1%–14.7%) with a statistically significant heterogeneity among studies (I 2 = 95.2%, 95% CI: 94.4%–95.8%, P < 0.001). Eleven studies were selected to analyze the prevalence of MVT in pancreatitis, ranging from 0.3% to 14% (Figure 3(c)). The pooled prevalence was 2.7% (95% CI: 1.4%–4.4%) and the heterogeneity remained (I 2 = 89.3%, 95% CI: 83.2%–92.5%).

Figure 3.

Figure 3

Open in a new tab

(a) Forest plots showing the prevalence of portal vein thrombosis (PVT) in pancreatitis. (b) Forest plots showing the prevalence of splenic vein thrombosis (SlpVT) in pancreatitis. (c) Forest plots showing the prevalence of mesenteric vein thrombosis (MVT) in pancreatitis.

3.5. Prevalence of SVT in AP and CP

Eighteen studies reported the prevalence of SVT in AP, ranging from 0.3% to 62.1% (Figure 4(a)). The pooled prevalence was 16.6% (95% CI: 10.0%–24.5%) with a statistically significant heterogeneity among studies (I 2 = 98%, 95% CI: 97.7%–98.2%, P < 0.001). Nine studies reported the prevalence of PVT in AP, ranging from 0.3% to 62.1% (Figure 4(b)). The pooled prevalence was 8.0% (95% CI: 2.4%–16.4%) with a statistically significant heterogeneity among studies (I 2 = 98.2%, 95% CI: 97.8%–98.5%, P < 0.001). Fifteen studies reported the prevalence of SplVT in AP, ranging from 1.2% to 20% (Figure 4(c)). The pooled prevalence was 10.4% (95% CI: 6.3%–15.3%) with a statistically significant heterogeneity among studies (I 2 = 94.8%, 95% CI: 93.3%–95.8%, P < 0.001). Eight studies reported the prevalence of MVT in pancreatitis, ranging from 0.3% to 14.0% (Figure 4(d)). The pooled prevalence was 2.6% (95% CI: 1.2%–4.5%) with a statistically significant heterogeneity among studies (I 2 = 90.4%, 95% CI: 83.9%–93.6%, P < 0.001).

Figure 4.

Figure 4

Open in a new tab

(a) Forest plots showing the prevalence of splanchnic vein thrombosis (SVT) in acute pancreatitis (AP). (b) Forest plots showing the prevalence of portal vein thrombosis (PVT) in acute pancreatitis (AP). (c) Forest plots showing the prevalence of splenic vein thrombosis (SlpVT) in acute pancreatitis (AP). (d) Forest plots showing the prevalence of mesenteric vein thrombosis (MVT) in acute pancreatitis (AP).

Twenty studies reported the prevalence of SVT in CP, ranging from 3% to 41.7% (Figure 5(a)). The pooled prevalence was 11.6% (95% CI: 8.5%–15.1%) with a statistically significant heterogeneity among studies (I 2 = 89.5%, 95% CI: 85.6%–91.9%, P < 0.001). Four studies reported the prevalence of PVT in CP, ranging from 1.5% to 4% (Figure 5(b)). The pooled prevalence was 3.5% (95% CI: 2.3%–4.8%) and there was no statistical heterogeneity between the two studies (I 2 = 0%, 95% CI: 0%–67.9%, P = 0.5947). Thirteen studies reported the prevalence of SplVT in CP, ranging from 1.5% to 41.7% (Figure 5(c)). The pooled prevalence was 12.8% (95% CI: 8.7%–17.6%) with a statistically significant heterogeneity among studies (I 2 = 88.8%, 95% CI: 83%–91.9%, P < 0.001). Two studies reported the prevalence of MVT in pancreatitis, ranging from 0.8% to 1.1% (Figure 5(d)). The pooled prevalence was 1.2% (95% CI: 0.4%–2.5%). There was no statistical heterogeneity between the two studies (P = 0.8506).

Figure 5.

Figure 5

Open in a new tab

(a) Forest plots showing the prevalence of splanchnic vein thrombosis (SVT) in chronic pancreatitis (CP). (b) Forest plots showing the prevalence of portal vein thrombosis (PVT) in chronic pancreatitis (CP). (c) Forest plots showing the prevalence of splenic vein thrombosis (SlpVT) in chronic pancreatitis (CP). (d) Forest plots showing the prevalence of mesenteric vein thrombosis (MVT) in chronic pancreatitis (CP).

3.6. Prevalence of SVT in HP and AIP

Only two studies reported the prevalence of SVT in HP, ranging from 7% to 19% (Figure 6(a)). The pooled prevalence was 12.2% (95% CI: 3.0%–26.5%) and there was no statistical heterogeneity between the two studies (P = 0.0914). Two studies reported the prevalence of PVT in HP, ranging from 2.8% to 11.5% (Figure 6(b)). The pooled prevalence was 6.6% (95% CI: 0.7%–17.8%) and there was no statistical heterogeneity between the two studies (P = 0.1056). Two studies reported the prevalence of SplVT in HP, ranging from 4.2% to 7.7% (Figure 6(c)). The pooled prevalence was 5.8% (95% CI: 2.1%–11.2%) and there was no statistical heterogeneity between the two studies (P = 0.437). There was no data on the prevalence of MVT in HP.

Figure 6.

Figure 6

Open in a new tab

(a) Forest plots showing the prevalence of splanchnic vein thrombosis (SVT) in hereditary pancreatitis (HP). (b) Forest plots showing the prevalence of portal vein thrombosis (PVT) in hereditary pancreatitis (HP). (c) Forest plots showing the prevalence of splenic vein thrombosis (SlpVT) in hereditary pancreatitis (HP).

Five studies reported the prevalence of SVT in AIP, ranging from 1.9% to 25% (Figure 7(a)). The pooled prevalence was 14.6% (95% CI: 6.1%–25.9%) and there was no statistical heterogeneity between the two studies (I 2 = 71.4%, 95% CI: 0%–86.7%, P = 0.0074). Two studies reported the prevalence of SplVT in AIP, ranging from 15% to 25% (Figure 7(b)). The pooled prevalence was 20.2% (95% CI: 9.8%–33.2%) and there was no statistical heterogeneity between the two studies (P = 0.4388). Only one study reported that the prevalence of PVT in AIP was 1.9%. There was no data on the prevalence of MVT in AIP.

Figure 7.

Figure 7

Open in a new tab

(a) Forest plots showing the prevalence of splanchnic vein thrombosis (SVT) in autoimmune pancreatitis (AIP). (b) Forest plots showing the prevalence of splenic vein thrombosis (SlpVT) in autoimmune pancreatitis (AIP).

3.7. Prevalence of SVT in Pancreatitis in Different Continent

The involved countries of all studies could be divided into three continents (Europe, America, and Asia). The incidences of SVT in pancreatitis were different among three continents. In Europe, twenty-two studies reported the prevalence of pancreatitis patients with SVT, ranging from 0.5% to 62.1% (Figure 8(a)). The pooled prevalence was 16.9% (95% CI: 10.7%–24.2%) with a statistically significant heterogeneity among studies (I 2 = 97%, 95% CI: 96.6%–97.4%, P < 0.001). Nine studies reported the prevalence of PVT in pancreatitis, ranging from 0.2% to 62.1% (Figure 8(b)). The pooled prevalence was 8.5% (95% CI: 1.6%–19.9%) with a statistically significant heterogeneity among studies (I 2 = 98.1%, 95% CI: 97.7%–98.4%). Sixteen studies reported the prevalence of SplVT in pancreatitis, ranging from 0.2% to 31.9% (Figure 8(c)). The pooled prevalence was 13.5% (95% CI: 7.6%–20.9%) with a statistically significant heterogeneity among studies (I 2 = 96.2%, 95% CI: 95.3%–96.8%, P < 0.001). Six studies reported the prevalence of MVT in pancreatitis, ranging from 0.3% to 10% (Figure 8(d)). The pooled prevalence was 3.2% (95% CI: 1.0%–6.8%) with a statistically significant heterogeneity among studies (I 2 = 88.8%, 95% CI: 77.4%–93.1%, P < 0.001).

Figure 8.

Figure 8

Open in a new tab

(a) Forest plots showing the prevalence of splanchnic vein thrombosis (SVT) in Europe. (b) Forest plots showing the prevalence of portal vein thrombosis (PVT) in Europe. (c) Forest plots showing the prevalence of splenic vein thrombosis (SlpVT) in Europe. (d) Forest plots showing the prevalence of mesenteric vein thrombosis (MVT) in Europe.

In America, fourteen studies reported the prevalence of SVT in pancreatitis, ranging from 1.6% to 46% (Figure 9(a)). The pooled prevalence was 11.5% (95% CI: 7.0%–16.8%) with a statistically significant heterogeneity among studies (I 2 = 95.7%, 95% CI: 94.6%–96.5%, P < 0.001). Five studies reported the prevalence of PVT in pancreatitis, ranging from 0.3% to 13% (Figure 9(b)). The pooled prevalence was 3.7% (95% CI: 1.3%–7.4%) with a statistically significant heterogeneity among studies (I 2 = 93.2%, 95% CI: 87.6%–95.6%, P < 0.001). Thirteen studies reported the prevalence of SplVT in pancreatitis, ranging from 0.8% to 22% (Figure 9(c)). The pooled prevalence was 9.2% (95% CI: 5.5%–13.7%) with a statistically significant heterogeneity among studies (I 2 = 94.8%, 95% CI: 93.2%–95.9%, P < 0.001). Five studies reported the prevalence of MVT in pancreatitis, ranging from 0.4% to 14% (Figure 9(d)). The pooled prevalence was 2.4% (95% CI: 0.7%–5.0%) with a statistically significant heterogeneity among studies (I 2 = 91.7%, 95% CI: 83.6%–94.8%, P < 0.001).

Figure 9.

Figure 9

Open in a new tab

(a) Forest plots showing the prevalence of splanchnic vein thrombosis (SVT) in America. (b) Forest plots showing the prevalence of portal vein thrombosis (PVT) in America. (c) Forest plots showing the prevalence of splenic vein thrombosis (SlpVT) in America. (d) Forest plots showing the prevalence of mesenteric vein thrombosis (MVT) in America.

In Asia, eight studies reported the prevalence of SVT in pancreatitis, ranging from 1.4% to 41.7% (Figure 10(a)). The pooled prevalence was 8.5% (95% CI: 3.7%–15.1%) with a statistically significant heterogeneity among studies (I 2 = 84.2%, 95% CI: 68.5%–90.3%, P < 0.001). Two studies reported the prevalence of PVT in pancreatitis, ranging from 1.8% to 1.9% (Figure 10(b)). The pooled prevalence in two studies was 2.3% (95% CI: 0.7%–4.6%). Six studies reported the prevalence of SplVT in pancreatitis, ranging from 1.4% to 41.7% (Figure 10(c)). The pooled prevalence was 10.1% (95% CI: 3.6%–19.5%) with a statistically significant heterogeneity among studies (I 2 = 87.8%, 95% CI: 74.5%–92.6%, P < 0.001). There was no data on the prevalence of MVT in pancreatitis in Asia.

Figure 10.

Figure 10

Open in a new tab

(a) Forest plots showing the prevalence of splanchnic vein thrombosis (SVT) in Asia. (b) Forest plots showing the prevalence of portal vein thrombosis (PVT) in Asia. (c) Forest plots showing the prevalence of splenic vein thrombosis (SlpVT) in Asia.

4. Discussion

The previous published meta-analysis that assessed the prevalence of SVT in patients with pancreatitis almost focused on AP, CP, HP, or AIP alone without systematic search. The prevalence varied from 1% to 24% in previous studies according to the type of pancreatitis and imaging technique used (US, EUS, CT, MRI, or ERCP) [30, 40, 55]. However, our study was remarkably different from the previous ones, as follows. (1) In the previous studies, most of them were single-center studies with a limited enrollment period and target population. By comparison, our meta-analysis included all studies conducted from 1958 to 2014 and 10560 patients with pancreatitis. Furthermore, we made a distinction on the source of patients according to the continents. (2) As we have known, SVT involves PVT, SplVT, and MVT. In contrast to the previous studies, we have paid more attention on the prevalence of PVT, SplVT, and MVT in pancreatitis. (3) Our research reported the prevalence of SVT on the basis of the different types of pancreatitis including AP, CP, HP, and AIP. However, there was no similar record in the previous studies.

Pancreatitis is associated with a variety of vascular complications including SVT. Clinically, SVT in pancreatitis is becoming common with the advancement of imaging technique. In the current systematic review and meta-analysis, we demonstrated that 13.6% of pancreatitis had SVT, 6.2% had PVT, 11.2% had SplVT, and 2.7% had MVT. The prevalence of SVT in pancreatitis showed some regional differences. We found that the prevalence of SVT in pancreatitis in Europe reached 16.9%, which was the highest among the three continents. Moreover, the prevalence of PVT, SplVT, and MVT in pancreatitis in Europe was higher than that in America or in Asia, respectively. We can find from the involved studies that the results came from nine countries of Europe, which were more than those from four of Asia and two of America. Compared with Asia, the prevalence of SVT in pancreatitis was 11.5% higher than that of 8.5% in Asia, but the prevalence of SplVT was a little lower in America.

Previous studies that reported the vascular complications of pancreatitis showed different prevalence of SVT in pancreatitis regardless of the type of pancreatitis. This meta-analysis demonstrated that the prevalence of SVT in AP was 16.6% higher than previous studies with a reported incidence of 1-2% [1]. The reason was that previous studies took PVT, SplVT, and MVT inclusion of SVT as numerator. The controversy also exists about the prevalence of SplVT in CP. The old series reported that the prevalence of SplVT in patients with CP varied between 2.5% and 25% [6, 51, 56, 57]. Our results showed 12.8% CP with SplVT, which was similar to that from a recent report by Butler et al. [58]. However, there was no detailed description on the prevalence of SVT in HP and AIP. Our results showed that the prevalence of SVT was 12.2% and 14.6% in HP and AIP, respectively. All of these could enrich the whole research on the prevalence of SVT in pancreatitis.

5. Limitation

Our study has several limitations. Firstly, the heterogeneity of available data from various years' studies was significant. Depending on advanced imaging technique, the majority of asymptomatic patients with SVT could be involved in research groups. Therefore, only the random-effects model was applied in our meta-analysis to generate a more conservative estimate of the proportion. Secondly, there are different results between Western and Asian countries. Besides the difference in the population race, lifestyle, and diagnostic level, the number of countries involved in the research is different. America included two countries and four countries were from Asia. Thirdly, there is no related research on the prevalence of SVT in HP and AIP. The final results may be not so typical.

6. Conclusion

This systematic review and meta-analysis attempt to quantify the incidence of SVT in pancreatitis according to the different forms of pancreatitis and regional distribution. Further studies are needed to analyze the relationship between natural history, clinical significance, long-term outcomes, and the prevalence of SVT in pancreatitis. The rate of SVT associated gastrointestinal bleeding and the security and reasonability of anticoagulation therapy on thrombosis are all needed to develop complete, large, multicentre, and collaborative studies.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

  • 1.Mallick I. H., Winslet M. C. Vascular complications of pancreatitis. Journal of the Pancreas. 2004;5(5):328–337. [PubMed] [Google Scholar]
  • 2.Harris S., Nadkarni N. A., Naina H. V., Vege S. S. Splanchnic vein thrombosis in acute pancreatitis: a single-center experience. Pancreas. 2013;42(8):1251–1254. doi: 10.1097/mpa.0b013e3182968ff5. [DOI] [PubMed] [Google Scholar]
  • 3.Stroup D. F., Berlin J. A., Morton S. C., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA. 2000;283(15):2008–2012. doi: 10.1001/jama.283.15.2008. [DOI] [PubMed] [Google Scholar]
  • 4.Higgins J. P. T., Thompson S. G., Deeks J. J., Altman D. G. Measuring inconsistency in meta-analyses. British Medical Journal. 2003;327(7414):557–560. doi: 10.1136/bmj.327.7414.557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Raina A., Yadav D., Krasinskas A. M., et al. Evaluation and management of autoimmune pancreatitis: experience at a large US center. The American Journal of Gastroenterology. 2009;104(9):2295–2306. doi: 10.1038/ajg.2009.325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Bernades P., Baetz A., Lévy P., Belghiti J., Menu Y., Fekete F. Splenic and portal venous obstruction in chronic pancreatitis. A prospective longitudinal study of a medical-surgical series of 266 patients. Digestive Diseases and Sciences. 1992;37(3):340–346. doi: 10.1007/bf01307725. [DOI] [PubMed] [Google Scholar]
  • 7.Gross J. B. Some recent developments pertaining to pancreatitis. Annals of Internal Medicine. 1958;49(4):796–819. doi: 10.7326/0003-4819-49-4-796. [DOI] [PubMed] [Google Scholar]
  • 8.Gonzalez H. D., et al. Splanchnic vein thrombosis in severe acute pancreatitis—is systemic anticoagulation indicated? Pancreatology. Pancreatology. 2011;11(3):p. 314. [Google Scholar]
  • 9.Shalimar S., Midha S., Bhardwaj P., Garg P. K. Long-term pain relief with optimized medical therapy including antioxidants in patients with chronic pancreatitis. Pancreatology. 2011;11:p. 32. doi: 10.1111/jgh.13410. [DOI] [PubMed] [Google Scholar]
  • 10.Huggett M. T., Tang K., Johnson G. J., Hatfield A. R., Pereira S. P., Webster G. J. Disease profile and long-term outcome of patients with autoimmune pancreatitis/IgG4 systemic disease. Gastroenterology. 2011;140(5) supplemet 1:p. S-545. doi: 10.1136/gut.2011.239301.15. [DOI] [Google Scholar]
  • 11.Rebours V., Vullierme M., Condat B. Digestive venous thrombosis (DVT) occuring during chronic pancreatitis is caused by local inflammation and not by thrombophilia. Pancreatology. 2010;10(2-3):p. 275. [Google Scholar]
  • 12.Pribramska V., Vege S. S., Trna J., Kamath P. S., Chari S. T. Natural history of splanchnic venous thrombosis in acute pancreatitis: a population-based study. Gastroenterology. 2009;136(5, supplement 1):p. A-541. doi: 10.1016/s0016-5085(09)62486-0. [DOI] [Google Scholar]
  • 13.Rebours V., Vullierme M. P., Condat B., et al. Digestive venous thrombosis (DVT) occurring during alcoholic acute or chronic pancreatitis is caused by local inflmmation and not by thrombophilia. Gastroenterology. 2010;138(5, supplement 1):p. S-392. [Google Scholar]
  • 14.Lawson J. A. A Dutch family with hereditary pancreatitis. Nederlands Tijdschrift voor Geneeskunde. 1981;125(8):304–312. [PubMed] [Google Scholar]
  • 15.Gonzelez H. J., Sahay S. J., Samadi B., Davidson B. R., Rahman S. H. Splanchnic vein thrombosis in severe acute pancreatitis: a 2-year, single-institution experience. HPB. 2011;13(12):860–864. doi: 10.1111/j.1477-2574.2011.00392.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Huggett M. T., Tang K., Johnson G. J., Hatfild A. R., Pereira S. P., Webster G. J. Disease profie and long-term outcome of patients with autoimmune pancreatitis/IgG4 systemic disease. Gut. 2011;60(supplemet 1):p. A8. [Google Scholar]
  • 17.Rebours V., Boudaoud L., Vullierme M.-P., et al. Extrahepatic portal venous system thrombosis in recurrent acute and chronic alcoholic pancreatitis is caused by local inflammation and not thrombophilia. The American Journal of Gastroenterology. 2012;107(10):1579–1585. doi: 10.1038/ajg.2012.231. [DOI] [PubMed] [Google Scholar]
  • 18.Britton E., Mahoney S., Garry J., Halloran C., Richardson P. PTH-095 portal hypertension due to splanchnic venous thrombosis following open or skunk wire necrosectomy of acute severe pancreatitis. Gut. 2014;63(supplement 1):p. A252. doi: 10.1136/gutjnl-2014-307263.541. [DOI] [Google Scholar]
  • 19.Sisman G., Erzin Y., Hatemi I., et al. Familial chylomicronemia syndrome related chronic pancreatitis: a single-center study. Hepatobiliary & Pancreatic Diseases International. 2014;13(2):209–214. doi: 10.1016/s1499-3872(14)60033-3. [DOI] [PubMed] [Google Scholar]
  • 20.Castiñeira-Alvariño M., Lindkvist B., Luaces-Regueira M., et al. The role of high fat diet in the development of complications of chronic pancreatitis. Clinical Nutrition. 2013;32(5):830–836. doi: 10.1016/j.clnu.2013.02.002. [DOI] [PubMed] [Google Scholar]
  • 21.Suero H. D. L., Raya E. C. V., Allende M. T. S., et al. Autoimmune pancreatitis in Barcelona as assessed by the international consensus diagnostic criteria (ICDC). Review of a series of 25 patients from two centers. Pancreatology. 2013;13(4, supplement 1):p. e17. doi: 10.1016/j.pan.2013.07.062. [DOI] [Google Scholar]
  • 22.Marra-López C., Marcaide A., de la Piscina P. R., et al. Chronic pancreatitis study in Txagorritxu-Araba university hospital (Vitoria-Gasteiz, Alava, Basque-Country) Pancreatology. 2013;13(4):p. e15. doi: 10.1016/j.pan.2013.07.053. [DOI] [Google Scholar]
  • 23.Vyas S., Skipworth J., Prete F., et al. Splanchnic venous thrombosis in acute pancreatitis: is there a role for routine systemic anticoagulation in severe acute pancreatitis? HPB. 2012;14:249–250. [Google Scholar]
  • 24.Sisman G., Erzin Y., Senturk H. The effect of Helicobacter pylori infection on the development of splenic vein thrombosis in chronic pancreatitis patients. Gastroenterology. 2012;142(2, supplement 1):p. S55. doi: 10.1016/S0016-5085(12)60214-5. [DOI] [Google Scholar]
  • 25.De León H., Allende H., Merino X., Balsells J., Guarner L., Molero X. Autoimmune pancreatitis in Barcelona as assessed by the Honolulu diagnostic criteria. Review of a series of 16 patients. Pancreatology. 2012;12(6):p. 565. doi: 10.1016/j.pan.2012.11.219. [DOI] [Google Scholar]
  • 26.Chooklin S., Hranat O. Spleen lesions in acute pancreatitis. Pancreatology. 2009;9(4):p. 494. [Google Scholar]
  • 27.Keck T., Marjanovic G., Fernandez-Del Castillo C., et al. The inflammatory pancreatic head mass: significant differences in the anatomic pathology of German and American patients with chronic pancreatitis determine very different surgical strategies. Annals of Surgery. 2009;249(1):105–110. doi: 10.1097/sla.0b013e31818ef078. [DOI] [PubMed] [Google Scholar]
  • 28.Makowiec F., Riediger H., Emmrich J., Kröger J., Hopt U. T., Adam U. Prophylactic splenectomy for splenic vein thrombosis in patients undergoing resection for chronic pancreatitis. Zentralblatt für Chirurgie. 2004;129(3):191–195. doi: 10.1055/s-2004-822782. [DOI] [PubMed] [Google Scholar]
  • 29.Malíková H., Kašpar M., Weichet J., Sobotovičová A., Drechslerová J. Vascular complications of acute pancreatitis. Ceska Radiologie. 2002;56(5):275–279. [Google Scholar]
  • 30.Dörffel Y., Wruck U., Rückert R. I., Romaniuk P., Dörffel W., Wermke W. Vascular complications in acute pancreatitis assessed by color duplex ultrasonography. Pancreas. 2000;21(2):126–133. doi: 10.1097/00006676-200008000-00004. [DOI] [PubMed] [Google Scholar]
  • 31.Arotcarena R., Heyries L., Moreau J., et al. Natural history of non alcoholic and non familial chronic pancreatitis. Results of a multicentre study. Gastroenterologie Clinique et Biologique. 1999;23(12):1368–1375. [PubMed] [Google Scholar]
  • 32.Friess H., Dervenis C., Avgerinos C., et al. Vascular complications in chronic pancreatitis. Hellenic Journal of Gastroenterology. 1997;10(3):220–224. [Google Scholar]
  • 33.Roesch W., Lux G., Riemann J. F., Hoh L. Chronic pancreatitis and surrounding organs. Fortschritte der Medizin. 1981;99(29):1118–1121. [PubMed] [Google Scholar]
  • 34.Sibert J. R. Hereditary pancreatitis in England and Wales. Journal of Medical Genetics. 1978;15(3):189–201. doi: 10.1136/jmg.15.3.189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Nordback I., Sisto T. Peripancreatic vascular occlusions as a complication of pancreatitis. International Surgery. 1989;74(1):36–39. [PubMed] [Google Scholar]
  • 36.Shalimar S., Midha S., Bhardwaj P., Garg P. K. Long-term pain relief with optimized medical therapy including antioxidants in patients with chronic pancreatitis. Gastroenterology. 2011;(5, supplement 1):p. S-547. doi: 10.1016/S0016-5085(11)62268-3. [DOI] [PubMed] [Google Scholar]
  • 37.Vege S. S., Pribramska V., Trna J., Kamath P. S., Chari S. T. Natural history of splanchnic venous thrombosis in acute pancreatitis: a population-based study. Pancreas. 2009;38(8):p. 1059. [Google Scholar]
  • 38.Easler J., Muddana V., Furlan A., et al. Portosplenomesenteric venous thrombosis in patients with acute pancreatitis is associated with pancreatic necrosis and usually has a benign course. Clinical Gastroenterology and Hepatology. 2014;12(5):854–862. doi: 10.1016/j.cgh.2013.09.068. [DOI] [PubMed] [Google Scholar]
  • 39.Muddana V., Easler J. J., Slivka A., Whitcomb D. C., Papachristou G. I., Yadav D. Prevalence, risk factors and management of peripancreatic venous thrombosis (PPVT) in acute pancreatitis (AP) Gastroenterology. 2012;142(5, supplement 1):p. S320. doi: 10.1016/S0016-5085(12)61201-3. [DOI] [Google Scholar]
  • 40.Mortelé K. J., Mergo P. J., Taylor H. M., et al. Peripancreatic vascular abnormalities complicating acute pancreatitis: contrast-enhanced helical CT findings. European Journal of Radiology. 2004;52(1):67–72. doi: 10.1016/j.ejrad.2003.10.006. [DOI] [PubMed] [Google Scholar]
  • 41.Pimentel F. H. B., Añez De Gómez C. I., Folena A. R. S., Silva R. C. M., Vieira A., Rolim E. G. Chronic pancreatitis complications in patients seen at the outpatient clinic. Gastrenterologia Endoscopia Digestiva. 2003;22(6):231–234. [Google Scholar]
  • 42.Mortelé K. J., Mergo P. J., Taylor H. M., Ernst M. D., Ros P. R. Splenic and perisplenic involvement in acute pancreatitis: determination of prevalence and morphologic helical CT features. Journal of Computer Assisted Tomography. 2001;25(1):50–54. doi: 10.1097/00004728-200101000-00009. [DOI] [PubMed] [Google Scholar]
  • 43.Sakorafas G. H., Sarr M. G., Farley D. R., Farnell M. B. The significance of sinistral portal hypertension complicating chronic pancreatitis. American Journal of Surgery. 2000;179(2):129–133. doi: 10.1016/S0002-9610(00)00250-6. [DOI] [PubMed] [Google Scholar]
  • 44.Rogers C., Klatt E. C. Splenic vein thrombosis in patients with acute pancreatitis. International Journal of Pancreatology. 1989;5(2):117–121. doi: 10.1007/BF02924412. [DOI] [PubMed] [Google Scholar]
  • 45.Hofer B. O., Ryan J. A., Jr., Freeny P. C. Surgical significance of vascular changes in chronic pancreatitis. Surgery Gynecology and Obstetrics. 1987;164(6):499–505. [PubMed] [Google Scholar]
  • 46.McElroy R., Christiansen P. A. Hereditary pancreatitis in a kinship associated with portal vein thrombosis. The American Journal of Medicine. 1972;52(2):228–241. doi: 10.1016/0002-9343(72)90072-1. [DOI] [PubMed] [Google Scholar]
  • 47.Talukdar R., Bhattacharrya A., Rao B., Sharma M., Reddy D. N. Clinical utility of the Revised Atlanta Classification of acute pancreatitis in a prospective cohort: have all loose ends been tied? Pancreatology. 2014;14(4):257–262. doi: 10.1016/j.pan.2014.06.003. [DOI] [PubMed] [Google Scholar]
  • 48.Jakchairoongruang K., Arjhansiri K. Prognostic value of contrast-enhanced computed tomography in acute pancreatitis. Asian Biomedicine. 2013;7(3):357–364. doi: 10.5372/1905-7415.0703.187. [DOI] [Google Scholar]
  • 49.Ishikawa T., Itoh A., Kawashima H., et al. Peripancreatic vascular involvements of autoimmune pancreatitis. Journal of Gastroenterology and Hepatology. 2012;27(12):1790–1795. doi: 10.1111/j.1440-1746.2012.07248.x. [DOI] [PubMed] [Google Scholar]
  • 50.Chowdhury S. D., Augustine J., Chacko A. Chronic pancreatitis amongst children in India. Pancreatology. 2011;11:p. 35. [Google Scholar]
  • 51.Agarwal A. K., Kumar K. R., Agarwal S., Singh S. Significance of splenic vein thrombosis in chronic pancreatitis. American Journal of Surgery. 2008;196(2):149–154. doi: 10.1016/j.amjsurg.2007.07.039. [DOI] [PubMed] [Google Scholar]
  • 52.Tsushima Y., Tamura T., Tomioka K., Okada C., Kusano S., Endo K. Transient splenomegaly in acute pancreatitis. British Journal of Radiology. 1999;72:637–643. doi: 10.1259/bjr.72.859.10624319. [DOI] [PubMed] [Google Scholar]
  • 53.Lin C.-C., Wang H.-P., Chen M.-F., et al. Chronic calcifying pancreatitis in Taiwan: a multicentric study and comparison with western countries. Hepato-Gastroenterology. 1997;44(15):842–848. [PubMed] [Google Scholar]
  • 54.Takase M., Suda K., Suzuki F., Nakamura T., Futagawa S. A histopathologic study of localized portal hypertension as a consequence of chronic pancreatitis. Archives of Pathology & Laboratory Medicine. 1997;121(6):612–614. [PubMed] [Google Scholar]
  • 55.Keeling D., Baglin T., Tait C., et al. Guidelines on oral anticoagulation with warfarin—fourth edition. British Journal of Haematology. 2011;154(3):311–324. doi: 10.1111/j.1365-2141.2011.08753.x. [DOI] [PubMed] [Google Scholar]
  • 56.Weber S. M., Rikkers L. F. Splenic vein thrombosis and gastrointestinal bleeding in chronic pancreatitis. World Journal of Surgery. 2003;27(11):1271–1274. doi: 10.1007/s00268-003-7247-6. [DOI] [PubMed] [Google Scholar]
  • 57.Heider T. R., Azeem S., Galanko J. A., et al. The natural history of pancreatitis-induced splenic vein thrombosis. Annals of Surgery. 2004;239(6):876–882. doi: 10.1097/01.sla.0000128685.74686.1e. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Butler J. R., Eckert G. J., Zyromski N. J., Leonardi M. J., Lillemoe K. D., Howard T. J. Natural history of pancreatitis-induced splenic vein thrombosis: a systematic review and meta-analysis of its incidence and rate of gastrointestinal bleeding. HPB. 2011;13(12):839–845. doi: 10.1111/j.1477-2574.2011.00375.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gastroenterology Research and Practice are provided here courtesy of Wiley

RESOURCES